Abstract: Disclosed is the use of a klotho protein or related compounds (especially KL1 or KL1 analogue) for treatment, and especially treatment of cancer, alone or together with other active pharmaceutical ingredients such as chemotherapeutic agents.

Abstract: Disclosed is the use of a klotho protein or related compounds for the diagnosis and treatment of cancer, alone or together with other active pharmaceutical ingredients such as chemotherapeutic agents or hormone-regulating agents.

Abstract: Disclosed are Klotho variant proteins in which residue Glu414 and/or residue Asp238 is substituted with an amino acid different than L-Glu or L-Asp, respectively, as well as polynucleotides encoding the variant proteins, and the use thereof in therapy, especially for the treatment of cancers, especially breast cancer and pancreatic cancer.

Abstract: Novel mutant ESR1 molecules and uses are disclosed.

Abstract: A method of analyzing bone formation or determination of cell state with regard to differentiation of osteoblasts and/or fibroblasts in a subject is provided, the method comprising detecting PCPE isoforms in a biological sample from the subject; and comparing the PCPE isoforms from the sample of biological fluid with PCPE isoforms of a predetermined standard or a sample obtained from healthy individuals.

Abstract: Disclosed are Klotho variant proteins in which residue Glu414 and/or residue Asp238 is substituted with an amino acid different than L-Glu or L-Asp, respectively, as well as polynucleotides encoding the variant proteins, and the use thereof in therapy, especially for the treatment of cancers, especially breast cancer and pancreatic cancer.

Abstract: A method of diagnosing fibrosis in a subject is provided, comprising the steps of: determining a level of PCPE in a body fluid sample obtained from said subject; and detecting an increased level of PCPE in said body fluid sample relative to a normal control level of PCPE, wherein said increased level of PCPE relative to normal control is indicative of fibrosis in said subject. Furthermore, methods for evaluating the pharmacological efficacy of a drug or a drug candidate in treatment of fibrosis in a patient and for monitoring change of fibrosis in a subject are provided.

Abstract: A method of diagnosing fibrosis in a subject is provided, comprising the steps of: determining a level of PCPE in a body fluid sample obtained from said subject; and detecting an increased level of PCPE in said body fluid sample relative to a normal control level of PCPE, wherein said increased level of PCPE relative to normal control is indicative of fibrosis in said subject. Furthermore, methods for evaluating the pharmacological efficacy of a drug or a drug candidate in treatment of fibrosis in a patient and for monitoring change of fibrosis in a subject are provided.

Abstract: Disclosed is the use of a klotho protein or related compounds (especially KL1 or KL1 analogue) for treatment, and especially treatment of cancer, alone or together with other active pharmaceutical ingredients such as chemotherapeutic agents.

Abstract: Disclosed is the use of a klotho protein or related compounds for the diagnosis and treatment of cancer, alone or together with other active pharmaceutical ingredients such as chemotherapeutic agents or hormone-regulating agents.

Abstract: Provided are methods and kits for determining predisposition to cancer by determining the presence or absence in a heterozygote form of the KLOTHO functional variant. Also provided are methods of designing treatment and treating cancer based on the increased predisposition to the cancer, and to determine the prognosis of a subject diagnosed with cancer.

Abstract: Use of PCPE, preferably PCPE-1, as a diagnostic marker.

Abstract: Disclosed are methods and compositions for increasing concentrations of GLP-1 receptor agonists in the body for the treatment of cancer, alone or together with other active pharmaceutical ingredients such as chemotherapeutic agents or hormone-regulating agents.

Abstract: Disclosed is the use of a klotho protein or related compounds for the diagnosis and treatment of cancer, alone or together with other active pharmaceutical ingredients such as chemotherapeutic agents or hormone-regulating agents.